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Simple Summary: Glioblastoma (GBM) is the most frequent and aggressive primary brain tumor.
Despite multimodal treatment, the prognosis of GBM patients remains very poor. Oncolytic virother-
apy is being evaluated as novel treatment for this patient group and clinical trials testing oncolytic
viruses have shown impressive responses, albeit in a small subset of GBM patients. Obtaining insight
into specific tumor- or patient-related characteristics of the responding patients, may in the future
improve response rates. In this review we discuss factors related to oncolytic activity of the most
widely applied oncolytic virus strains as well as potential biomarkers and future assays that may
allow us to predict response to these agents. Such biomarkers and tools may in the future enable
personalizing oncolytic virotherapy for GBM patients.
Abstract: Oncolytic virus (OV) treatment may offer a new treatment option for the aggressive
brain tumor glioblastoma. Clinical trials testing oncolytic viruses in this patient group have shown
promising results, with patients achieving impressive long-term clinical responses. However, the
number of responders to each OV remains low. This is thought to arise from the large heterogeneity of
these tumors, both in terms of molecular make-up and their immune-suppressive microenvironment,
leading to variability in responses. An approach that may improve response rates is the personalized
utilization of oncolytic viruses against Glioblastoma (GBM), based on specific tumor- or patient-
related characteristics. In this review, we discuss potential biomarkers for response to different OVs
as well as emerging ex vivo assays that in the future may enable selection of optimal OV for a specific
patient and design of stratified clinical OV trials for GBM.
Keywords: oncolytic viruses; glioblastoma; clinical trials; biomarkers; personalized oncolyticvi-
rotherapy
1. Introduction
Oncolytic viral therapy or virotherapy is a form of immunotherapy showing promising
results for cancers with poor prognosis [1]. In this approach, oncolytic viruses (OVs)
are employed to kill tumor cells, while in parallel stimulating an anti-tumor immune
response [2]. OVs exhibit either natural tropism to malignant cells or their genome is altered
to confer them higher specificity for malignant cells [3]. Viruses from ten different families
(Adenoviridae, Herpesviridae, Paramyxoviridae, Reoviridae, Retroviridae, Picornaviridae,
Parvoviridae, Poxviridae, Rhabdoviridae, Alphaviruses) have thus far been utilized as
oncolytic virus platforms in clinical trials for various cancer types [2].
One deadly type of cancer is glioblastoma multiforme (GBM), the most common and
aggressive primary brain tumor [4]. The standard treatment consists of maximal safe
surgical resection followed by radiotherapy plus concomitant and adjuvant temozolomide
chemotherapy. However, the median overall survival among all GBM patients is less than
one year, and only 15 months in patients receiving complete standard treatment with 3-year
survival being less than 10% [5,6]. In the past decades, numerous therapeutic approaches
Cancers 2021, 13, 614. https://doi.org/10.3390/cancers13040614 https://www.mdpi.com/journal/cancers
Cancers 2021, 13, 614 2 of 22
have been tested in clinical trials, with disappointing outcomes. The main obstacles
in treating GBM include its infiltrative growth, its intrinsic resistance to chemo- and
radiotherapy, its notorious intratumoral heterogeneity with dynamic changes in subclones
facilitating treatment escape, its protected location behind the blood-brain-barrier and
the immunological ‘cold’ microenvironment of these tumors. These hurdles to more
conventional therapies, as well as the dismal prognosis of GBM patients, have encouraged
scientists and clinicians to develop and evaluate the local application of various types of
oncolytic viruses in this patient group. Table 1 summarizes the most commonly applies
OVs in GBM trials. The OVs differ in their primary attachment molecules to host receptors
as well as in the source of their tumor selectivity, which may be derived from a natural
tropism to cancer cells or by genetic engineering.
Table 1. Characteristics of the most commonly used Oncolytic viruses (OVs) in glioblastoma multiforme (GBM) clinical trials.
Family Genome OV Examples Genetic Engineering Entry Receptor Tumor Specificity
HSV1716 ICP34.5-deleted HVEM, 3-O-sulfated
heparin sulfate and nectin-2
Defects in the p16/Rb, PKR or
interferon pathways [7]
Herpesvirus dsDNA
G207 ICP34.5 and ICP6-deleted mutant oHSV
HVEM, 3-O-sulfated
heparin sulfate and nectin-2
Defects in the p16/Rb, PKR or
interferon pathways [8]
G47∆ ICP34.5, ICP6 and α47-deleted mutant oHSV
HVEM, 3-O-sulfated
heparin sulfate and nectin-2
Defects in the p16/Rb, PKR or
interferon pathways [9]
rQnestinHSV-1
ICP34.5-deleted mutant oHSV, in
which γ134.5 gene was reinserted
under control of nestin promoter
HVEM, 3-O-sulfated
heparin sulfate and nectin-2 Expression of nestin [10]
Adenovirus dsDNA
Onyx-015 E1B-55k and E3B -deleted mutantgroup C adenovirus CAR
Defects in p53 pathway, defects in
cell cycle, late viral
RNA export [11]
delta24-RGD
24-base pair deletion in the E1A
gene and insertion of an RGD
sequence in the viral knob
CAR, αvβ3 and αvβ5




strain with insertion of the human
carcinoembryonic antigen gene
CD46, nectin-4, SLAM Overexpression of CD46, defectsin the interferon pathway [13]
NDV Natural tropism Sialic acids Defects in theinterferon pathway [14]
Reovirus dsRNA R124 Natural tropism JAM-A, Nogo Receptor NgR1 Defects in the Rassignaling pathway [15]
Picornaviridae (+) ssRNA PVSRIPO
Poliovirus type 1 (Sabin) vaccine
with replacement of the internal
ribosomal entry site (IRES) with
the human rhinovirus type 2 IRES
CD155 Overexpression of CD155 [16,17]
Parvovirus H1 ssDNA ParvovirusH-1PV Natural tropism Sialic acids
Defects in interferon pathway,
defects in cell
proliferation pathways [18]
In a recent review, Chiocca et al. summarized the findings [19] from all the recent
GBM oncolytic virotherapy trials and illustrated that a subgroup of GBM patients responds
exceptionally well to OV treatments, with survivors at 36-months, and with some patients
exhibiting long term remission [20,21]. This phenomenon has also been observed in OV
trials for other cancer types. For instance, a phase II clinical trial employing an oncolytic
herpes simplex virus 1 for stage IIIC or IV melanoma showed 26% overall response [22].
These observations raise the question: would the responding patients have been
the same individuals if they had been treated with any other OV, or are we looking at
responders to a specific OV? In other words, is the elicited immune response a generalized
one for all types of OVs, or does each OV elicit a specific anti-tumor immune response?
The latter would suggest that response rates may be significantly increased if we are
able to define which OV is best suited for a particular patient. Identification of robust
predictive biomarkers for OV response would allow future design of stratified clinical trials
employing multiple OV strains. The replication efficiency of the virus is thought to be
of importance for generation of the subsequent inflammatory and anti-tumor responses.
Moreover, host immune status is also expected to contribute to the efficacy of OV treatment.
This review, therefore, focuses on tumor and host resistance mechanisms to viral infection,
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replication and oncolysis and discusses potential biomarkers that have previously been
reported in relation to sensitivity or resistance to the most frequently employed OVs in
preclinical and clinical GBM research.
2. Glioblastoma
2.1. Heterogeneity, Stem Cells and Therapy Resistance
Common molecular abnormalities involved in the evolution of glioblastomas include
aberrations in the oncogenes (EGFR, PDGF and its receptors) and tumor suppressor genes
(p16INK4a, p14ARF, PTEN, RB1, and TP53), which are often observed in other human
cancers as well [23]. GBM is also characterized by inter-tumoral heterogeneity, which is
highlighted by the classification of GBMs into three subgroups: proneural, classical and
mesenchymal [24,25]. Each subtype is characterized by specific gene expression patterns
and molecular abnormalities, resulting in different clinical treatment outcomes [25,26].
Proneural subtype has the most favorable prognosis among the three subtypes; aberra-
tions in the isocitrate dehydrogenase 1 (IDH1) gene and the platelet-derived growth factor
receptor A (PDGFRA) define this subgroup. The classical subgroup is characterized by
the amplification of EGFR, lack of TP53 mutations and often with homozygous CDKN2A
deletions [26]. Lastly, the mesenchymal subtype is the most aggressive and it is char-
acterized by aberrations in the neurofibromin 1 (NF1) and PTEN genes [23]. It is also
characterized by a pro-inflammatory environment compared with the other subtypes [27].
It was hypothesized that one underlying cause for this was the higher incidence of tumor-
associated antigens (TAAs), however this could not be proven, as specific tumor antigens
are expressed in each subtype [27]. Nevertheless, this classification has not led to altered or
adapted treatment approaches [28,29].
Apart from intertumoral heterogeneity, intra-tumoral heterogeneity poses another
therapeutic obstacle in treatment of GBM, allowing escape of subclones from (targeted)
therapies and driving treatment resistance. This heterogeneity was captured by genome-
wide and single cell RNA studies, which showed tumor cells with different transcriptional
profiles within the same tumor [30,31]. In addition, it was shown that within the same
tumor, different subtypes can coexist, highlighting the heterogeneity that characterizes
GBM [31]. In another study, paired primary and recurrent tumor tissue samples were
analyzed to determine the persistence of possible drug targets. The results showed that
the molecular targets between primary and recurrent tumors changed by 90% [32]. This
may explain the failure of drugs that target specific molecular mutations in GBM, such as
the EGFR [33].
Eventually, most of the patients experience tumor relapse due to therapeutic resis-
tance [29]. This therapeutic resistance is mainly attributed to glioblastoma stem cells
(GSCs), which activate DNA repair mechanisms to promote survival after chemo- and
radiotherapy [34]. Additionally, outgrowth of resistant subclones and downregulation
of targeted molecules contribute to drug resistance. Furthermore, the highly infiltrative
nature of GSCs makes total surgical resection of the tumor impossible [35]. The remain-
ing and/or treatment-resistant clones will eventually generate functional vessels for the
nutrient transport and develop tumor recurrence [34].
2.2. GBM Microenvironment: Local Immunosuppressive Mechanisms
Glioblastoma arises in the central nervous system (CNS) [36], which is an immunologi-
cally distinct site. In the past, the CNS was considered an immune privileged site, due to its
unique properties. For instance, the blood brain barrier, which tightly regulates the trans-
portation of the immune cells from the periphery to the CNS; the lack of antigen presenting
cells in a non-inflamed state; and more importantly the lack of a classic lymphatic sys-
tem [37–39]. The concept of CNS being immune privileged has now been revised. Recent
studies have shown that antigens derived from the CNS can efficiently elicit an immune
response [40]. More importantly, Louveau et al. [41] discovered a functional lymphatic sys-
tem, parallel to the dural sinuses, a possible route of transportation of antigen-presenting
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cells to the deep cervical lymph nodes, where they can present CNS-derived antigens and
prime T cells. These recent studies have provided evidence that CNS-derived antigens
can mount a vigorous immune response, offering ground to investigate immunotherapy
approaches for GBM.
The GBM environment is characterized by the high influx of tumor-associated macrop-
hages (TAMs). In a non-inflamed state, the myeloid composition of the CNS consists of
the tissue-resident macrophages that arise from the yolk sac, the microglia [42]. How-
ever, in GBM, the microenvironment is comprised mainly of a mixture of microglia and
infiltrating monocytes from the periphery. Glioma cells produce a milieu of monocyte
chemoattractant proteins along with other factors, leading to disruption of the blood-brain
barrier and facilitating recruitment of monocytes from the periphery [43]. When monocytes
arrive at the tumor site, glioma cells drive their polarization to an immunosuppressive
M2 phenotype [44,45]. These M2-like TAMs promote tumor growth and migration as
well as the immune invasion by hampering the adaptive immunity [44,46,47]. TAMs are
the most abundant immune cell population in GBM and can consist up to 50% of the
GBM tumor mass. Their importance in tumor growth is highlighted by the correlation
between increased TAM numbers and worse prognosis in GBM patients; furthermore,
TAM infiltration has been associated with the mesenchymal subtype of GBM, being the
most aggressive one [48,49].
Another feature that facilitates the local immune suppression in GBM is T cell dysfunc-
tion. Severe T cell exhaustion is observed in GBM, which is characterized by upregulation
of expression of co-inhibitory molecules like PD-1, LAG-3 and TIM-3 [50]. Furthermore,
an increase in numbers of the regulatory T cells (Tregs), which can suppress the antigen-
specific T cells, was found in high grade gliomas compared to low grade gliomas [51]. The
recruitment of Tregs at the tumor site is mainly facilitated by the production of the attrac-
tant indoleamine 2,3 dioxygenase (IDO) by gliomas [52]. Another facet that contributes to
the ‘’cold” tumor microenvironment is the relatively low mutational burden of GBM cells,
associated with limited expression of neoantigens [53,54]. Taken together, GBM has all the
characteristics of a tumor with low immunogenicity. The M2-like macrophages that are
abundant at the tumor site, the dysfunctional T cells and the low neoantigen expression
are some of the barriers that we need to overcome to design successful immunotherapies.
Considering all of the above, a therapeutic strategy that is not hindered by specificity
for a single molecular target or differentiation state of tumor cells, that is delivered locally in
a single surgical intervention, hence bypassing the BBB, that is self-perpetuating in its anti-
tumor activity, and which can overcome the immune-suppressive tumor microenvironment,
may offer opportunities for achieving therapeutic responses in glioblastoma patients.
Oncolytic viruses offer such a treatment strategy.
3. Factors Affecting OV Therapy in GBM
Several oncolytic virotherapy clinical trials have shown impressive and durable re-
sponses in a subset of patients, indicating that OVs might be a very promising thera-
peutic tool for treating GBM. The establishment of an efficient viral infection, lysis of
tumor cells, viral spreading and anti-tumor immune activation, all depends on multiple
factors (Figure 1). It is therefore conceivable that we may improve OV efficacy if we take
these factors into account when selecting patients for treatment.




Figure 1. OV restriction mechanisms of GBM tumors. Infiltration of NK cells and tumor-associated 
macrophages (TAMs) at the tumor site, activation status of autophagy, expression of viral entry 
molecules and viral sensors (e.g., cGAS-STING) that lead to constitutive active type I interferon 
pathways, all could hamper the OV replication and oncolysis. Furthermore, cathepsin B expression 
and expression of specific proteins that drive specific tumor replication (e.g., nestin) could deter-
mine the OV efficacy. Created with BioRender.com. 
3.1. Viral Entry Molecule Expression 
Tumor cell infection and oncolysis are a prerequisite for mounting an inflammatory 
response in the tumor microenvironment and ultimately generating an anti-tumor immune 
response. This depends on the cell entry possibilities for the virus. As GBM cells are not the 
natural host cells for entry of most viruses, low levels or even lack of receptor molecules on 
these cells can form the first obstacle to virotherapy. It has been shown that tremendous 
inter-tumoral variability exists in expression levels of specific adenovirus and reovirus entry 
molecules on patient-derived GBM cells [55,56]. As a result, various retargeting strategies 
have been applied to overcome such limitations, including EGFR and integrin retargeting 
of OVs [57]. Therefore, OV efficacy could potentially be enhanced by stratification of pa-
tients based on expression of specific viral receptor molecules in their tumors. 
3.2. Status of Oncogenic Signaling Pathways Affected in Glioblastoma 
Many OVs applied in glioma studies are genetically engineered or have naturally 
evolved to exploit oncogenic signaling pathways in cancer cells, such as the Ras, Rb, p53 
or nucleotide synthesis pathways [58]. Therefore, OV efficacy could potentially be en-
hanced by stratification of patients based on activation status or presence of mutations in 
targeted pathways. 
Another targeting approach is by the insertion of tumor-specific promoters to drive 
specific viral replication in tumor cells and avoid toxicity to normal tissue [59]. Various 
promoter candidates have been applied to design tumor-specific promoter-driven OVs, 
including nestin, survivin, cyclooxygenase-2 (COX-2), C-X-C chemokine receptor type 4 
Figure 1. OV restriction mechanisms of GBM tumors. Infiltration of NK cells and tumor-associated macrophages (TAMs) at
the tumor site, activation status of autophagy, expression of viral entry molecules and viral sensors (e.g., cGAS-STING) that
lead to constitutive active type I interferon pathways, all could hamper the OV replication and oncolysis. Furthermore,
cathepsin B expression and expression of specific proteins that drive specific tumor replication (e.g., nestin) could determine
the OV efficacy. Created with BioRender.com.
3.1. Viral Entry Molecule Expression
T mor cell infection and oncolysis are a prerequisite for mounting an inflammatory
response in the tumor microenvironment and ultimately generating an anti-tumor immune
response. This depends on the cell entry possibilities for the virus. As GBM cells are
not the natural host cells for entry of most viruses, low levels or even lack of receptor
molecules on these cells can form the first obstacle to virotherapy. It has been shown
that tremendous inter-tumoral variability exists in expression levels of specific adenovirus
and reovirus entry molecules on patient-derived GBM cells [55,56]. As a result, various
retargeting strategies have been applied to overcome such limitations, including EGFR
and integrin retargeting of OVs [57]. Therefore, OV efficacy could potentially be enhanced
by stratification of patients based on expression of specific viral receptor molecules in
their tumors.
3.2. Status of Oncogenic Signaling Pathways Affected in Glioblastoma
Many OVs applied in glioma studies are genetically engineered or have naturally
evolved to exploit oncogenic signaling pathways in cancer cells, such as the Ras, Rb,
p53 or nucleotide synthesis pathways [58]. Therefore, OV efficacy could potentially be
enhanced by stratification of patients based on activation status or prese ce of mutations
in t rgeted thways.
Another targeting approach is by the insertion of tumor-specific promoters to drive
specific viral replication in tumor cells and avoid toxicity to no mal tissue [59]. Various
promoter candidates have been applied o design tumor-specific promoter-driven OVs,
ncluding nestin, surv vin, cyclooxygenase-2 (COX-2), C-X-C chemokine receptor type 4
(CXCR4), hypoxia inducibl factor-1 (HIF 1) and tel meras [10,60–63]. Considering the
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intertumoral heterogeneity in transcription profiles of GBM, it would be expected that the
response to such OVs might vary between GBM subtypes. One could hypothesize that
GBM with proneural features might be more sensitive to viruses targeting cells expressing
neuronal progenitor genes (e.g., nestin), whereas tumors of mesenchymal subtype may
be more sensitive to viruses in which replication is driven by the inflammation-activated
COX-2 or CXCR4 promoter [62–64].
3.3. Innate Anti-Viral Responses
Upon cell entry, antiviral host defenses may be activated that counteract a productive
lytic cycle and progeny production. There is a plethora of innate sensors that could lead to
clearance of the infected cell and halt the viral spreading, leading to resistance to OV therapy.
As soon as the cell is infected, the viral pathogen-associated molecular patterns (PAMPs)
are sensed by pattern recognition receptors (PRRs). These PRRs include Toll-like receptors
(TLRs) [65], RIG-I-like receptors (retinoic acid-inducible gene-I-like receptors, RLRs) [66], C-
type lectin receptors (CLRs) [66], oligomerization domain containing receptors {(NOD-like
receptors (NLRs)} [66], cyclic GMP-AMP synthase (cGAS) [67] and absent in melanoma 2
(AIM2)-like receptors (ALRs) [68]. The recognition of the viral PAMPs from the host PRRs
results in interferon type I (IFNα, IFNβ, IFN-ε, IFN-κ, IFN-ω, IFN-δ, IFN-ζ and IFN-τ) and
interferon type III (IFN-λς) production, as well as the expression of interferon stimulated
genes (ISGs) and other proinflammatory cytokines and chemokines [69,70].
Although the aforementioned PRRs have been extensively studied, not many studies
have attempted to correlate their overexpression in tumor cells with OV resistance; but
rather with the aftermath of the recognition, the antiviral interferon pathways. However, a
few studies have implicated the cytosolic DNA sensing pathway to oncolytic herpes virus-1
resistance (see below). The main sensor of dsDNA in the cytoplasm is the cGAS, which
recognizes dsDNA viruses and reverse transcribing RNA viruses like HIV-1. As soon as
cGAS is activated, it synthesizes cGAMP which activates the adaptor protein stimulator of
interferon genes (STING) [71]. Stimulation of STING leads to the activation of IRF3 and
NFκB [71]. Interferon gamma inducible protein 16 (IFI16) is another sensor of dsDNA that
signals via STING to activate IRF3 and NFκB resulting in IFNβ production [72].
Ultimately, viral detection by the aforementioned sensors will lead to the activation
of host defenses such as the production of type I and type III interferons. These have
distinct receptors, however, both activate a signaling cascade via receptor-associated protein
tyrosine kinases Janus kinase 1 (JAK1) and tyrosine kinase 2 (TYK2), which activate the
activator of transcription 1 (STAT1) and STAT2, which subsequently form a complex with
the IFN regulatory factor 9 (IRF9), the ISGF3 complex [73]. This complex translocates
to the nucleus, resulting in the expression of more than 300 ISGs and pro-inflammatory
molecules and establishing an anti-viral state in the infected cell [74,75]. The cytokine and
chemokine milieu produced by the infected cell also acts in a paracrine manner to induce
an ISG-mediated anti-viral state in the (uninfected) adjacent cells. Some of these ISGs, such
as GTPase myxovirus resistance 1 (MxA), ribonuclease L (RNaseL) and protein kinase R
(PKR) have direct antiviral activity. For instance, MxA monomers reside in the cytoplasm
and upon binding to viral components can degrade them [76]. PKR regulates a plethora of
signaling pathways and its role in antiviral response and inhibition of host translation is
considered crucial upon virus infection [76].
The anti-viral IFNs are major determinants of OV efficacy. Many OVs exploit the IFN
pathway defects to successfully replicate in tumor cells. For instance, it has been shown
that STING pathway is correlated with oncolytic herpes virus-1 resistance (see below).
However, new evidence shows that this advantage in viral replication may not correlate
with tumor eradication in vivo [77]. This may be explained by the inability of oncolytic
viruses to induce immunogenic cell death in STING-deficient tumor cells, thus hampering
the induction of innate and adaptive immunity [78]. Identifying specific defects in the IFN
pathway that may ‘assist’ the viral replication without harming the induction of antitumor
immunity, could lead to identification of predictive biomarkers for OV sensitivity.
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3.4. The Autophagic Response to Viral Infections
There is growing evidence that the role of autophagy in the infectious cycle of many
viruses is critical. Autophagy is an evolutionary conserved adaptive process in which the
cells attempt to maintain their homeostasis [79,80]. It can be triggered by different types of
stress, such as hypoxia, nutrient deprivation and infection [81]. The role of autophagy is to
remove detrimental cytosolic material such as protein aggregates and damaged organelles.
During this process, a phagophore engulfs cytosolic material to form an autophagosome,
which subsequently fuses with a lysosome to degrade its cytoplasmic content [81].
Autophagy is activated by the infected cell to degrade and remove the virions from
the cell, a process called xenophagy [82]. TLRs, RLRs and cGAS signaling pathways,
among others, lead to autophagy activation to enhance the interferon production and
create an anti-viral milieu [83]. Notably, plasmacytoid dendritic cells (pDCs) which lack the
autophagy protein 5 (Atg5) showed decreased TLR7-dependent IFNα and IL-12 production
after VSV and Sendai virus infection, indicating the importance of autophagy for mounting
an anti-viral response [84]. Additionally, autophagy was shown to have anti-viral effects
against Sindbis virus and Rift Valley Fever Virus infection [85,86]. On the other hand,
many viruses have developed mechanisms to exploit autophagy in favor of their viral
replication. For example, herpesvirus and dengue virus were shown to enhance autophagy
to promote cell survival in order to establish a successful infection and enhanced viral
replication [87,88]. Moreover, rapamycin, an autophagy inducer, was shown to increase the
viral replication of various oncolytic viruses in tumor cells, including adenovirus, reovirus,
poliovirus, herpes virus, NDV and myxoma virus [89–94]. In line with these findings,
it was shown that knocking out two key autophagy genes (ATG5 or ATG10) impaired
virus-induced lysis of cancer cells by a modified oncolytic adenovirus (delta24-RGD) [95].
Furthermore, co-treatment with Everolimus, a rapamycin derivative, and delta24-RGD
enhanced autophagic dependent cell death in an in vivo glioma model [96].
The double-sided role of autophagy in oncolytic virus efficacy has captured the
attention of the research community and it has been extensively reviewed [97,98]. The
results thus far suggest that, for certain OVs, the tumor cells’ ability to activate autophagy
can contribute to the degree of viral replication, and ultimately the therapeutic efficacy of
the viral treatment.
4. Potential Biomarkers for Sensitivity to Oncolytic Viruses
The different OV strains employed in GBM immunotherapy utilize different cell
entry receptors of entry and their cell killing mechanisms are distinct from each other.
Furthermore, each OV strain triggers the host responses in diverse ways. Available in vitro
and in vivo data provides numerous leads to pathways and molecules involved in OV
sensitivity or resistance. OV trials are increasingly incorporating trial-associated (immune)
monitoring studies to gain insight into the in situ mechanisms involved in clinical OV
therapy. Such valuable data may yield relevant information for identifying potential
biomarkers related to response to OV therapy in GBM.
4.1. Oncolytic Herpes Simplex Virus
Oncolytic HSV-1 (oHSV) is an enveloped double-stranded DNA virus that belongs
to the alpha-herpesvirus subfamily [99]. It is a neurotropic virus and therefore requires
engineering for tumor-restricted replication [100]. Modified oHSV-1 variants that have
been tested in glioma patients are G207, G47∆, HSV1716 and rQNestin-34.5 [9]. Safety
and feasibility of local oHSV injection in GBM was shown in two phase 1 trials testing
G207 and HSV1716 [7,8]. However, in both studies viral replication was detected in only a
few patients; 3 out of 6 and 2 out of 12 patients, respectively. These results suggest that
the replication of the virus was restricted in some patients. In addition, seroconversion
was observed in some patients indicating that the antiviral immune response may have
contributed to the rapid clearance of the virus [7,8]. In an effort to understand these
restricting mechanisms, Peters et al. studied G207 infection in vitro and found glioma stem
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cells (GSCs) to be non-permissive to infection [101]. G207 virus contains mutations in both
copies of the γ34.5 gene to prevent neurovirulence, however, in GSCs this deletion results
in a translational shut down preventing the production of progeny virions [101]. Other
oHSV-1 variants designed to express the γ34.5 protein under a tumor-specific promoter
such as the rQNestin-34.5, might enhance the oncolytic activity of the virus in GSCs [10].
Another modified HSV-1 is Talimogene laherparepvec (T-VEC) which is the first Food
and Drug Administration (FDA) approved oncolytic virus and is indicated for treatment of
patients with advanced melanoma [102]. Numerous clinical trials have employed T-VEC,
however, no biomarkers for response have been described thus far. In a clinical study in
melanoma patients, a favorable outcome was observed in a subgroup of patients with
unresectable Stage III or IV M1a disease [103]. Recently, an in vitro study in melanoma cell
lines revealed that STING expression can restrict T-VEC-mediated oncolysis and loss of its
expression may confer sensitivity to oncolysis [104].
4.2. Oncolytic Adenovirus
Adenoviruses are non-enveloped double-stranded DNA viruses [59]. Oncolytic ade-
noviruses have been extensively explored and utilized in many clinical trials against
several cancers [105]. Conditionally replicating adenoviruses (CRAds) have been modified
in diverse ways to target oncogenic pathways frequently mutated cancers such as the
retinoblastoma (Rb) or the p53 pathway [58,106]. Dl1520 (ONYX-015) was the first CRAd
tested in a phase I clinical trial for recurrent gliomas, in which the safety of local peritumoral
injection of the virus was shown [107]. Several possible selectivity mechanisms have been
proposed for dI1520, including p53/p14ARF defects, aberrant late mRNA transport and
cell cycle disruption, all of which may relate to the functions of the early viral E1B-55k gene
which is deleted in this virus [11]. Whether any of these factors can serve as biomarkers for
dI1520 response has not been evaluated.
The results of another phase I clinical study against recurrent malignant gliomas using
the CRAd delta24-RGD (DNX-2401) were recently published [20]. This OV was engineered
to selectively replicate in tumor cells with dysfunctional Rb pathway, which is the case in
approximately 80% of GBM tumors [12,58]. Impressive anti-tumor effects were found, with
17% of the treated patients surviving beyond 3 years [20]. Another early clinical trial with
this CRAd was conducted in our institute in patients with recurrent GBM (NCT01582516).
A subgroup of patients revealed high concentrations of different cytokines in post treatment
CSF samples, indicating that delta24-RGD can induce an inflammatory microenvironment,
which is potentially key for its therapeutic efficacy [108]. Whether specific cytokines can
serve as biomarkers for response requires further investigation.
Very few studies have focused on elucidating the resistance mechanisms in the non-
responder patients in oncolytic adenoviral trials. In one study, it was demonstrated that the
IFN signaling pathway was upregulated in Ad5/3-∆24-resistant ovarian tumors compared
to untreated tumors [109]. Moreover, the authors showed that the MxA, an ISG which is
induced by IFN type I or type III signaling could provide a predictive marker for resistance
to oncolytic adenoviral therapies [109,110].
Of great interest are the studies that have focused on the pre-treatment immune status
of patients receiving oncolytic adenovirus. Specifically, it was shown that chronic inflam-
mation was a negative predictive marker for response to oncolytic adenovirus therapy
in different types of cancer [111]. Furthermore, high-mobility group box 1 (HMGB1), a
nuclear protein secreted by immune cells and which is associated with a pro-inflammatory
state and immunological cell death, could serve as a predictive and prognostic marker
for oncolytic virotherapy with adenoviruses. The study suggested that patients with
low serum HMGB1 have more robust anti-tumor responses after oncolytic adenovirus
therapy [112]. It was hypothesized that a higher pro-inflammatory state as measured by
HMGB1, leads to inhibition of viral replication. These results may suggest that the use of
immunosuppressants for a limited amount of time during post virus administration, may
improve response rates in this subgroup of patients.
Cancers 2021, 13, 614 9 of 22
Lastly, in a study using pancreatic cell lines it was shown that high expression of
cyclin D1 enhances delta24-RGD-induced cytotoxicity [113]. Cyclin D1 activates the cyclin-
dependent kinase 4 and 6 (CDK4 and CDK6), which then phosphorylates the Rb protein
resulting in cell cycle progression. Over-expression of cyclin D1 has been observed in
many cancer types like head and neck squamous cell carcinomas (HNSCC), pancreatic
and breast cancer [114]. In GBM, the highest expression of cyclin D1 was observed in
the proneural subtype, which may suggest that this subtype would benefit more from
delta24-RGD treatment.
4.3. Oncolytic Retrovirus
Replication-competent retroviruses are a relative newcomer to the OV field. These
are single-stranded RNA viruses. Originally, retroviruses were applied in gene therapy
approaches, however, it was later shown that replication competence of retroviruses can
provide a powerful tool for gene delivery of anticancer agents in tumors [115]. Vocimagene
amiretrorepvec (Toca 511) is a replicating γ-retrovirus derived from murine leukemia virus
and is engineered to encode a yeast cytosine deaminase (CD) gene [116]. In the presence
of the prodrug 5-fluorocytosin (5-FC), CD converts 5-FC to the potent anti-cancer drug
5-fluorouracil (5-FU). The results from a phase I clinical trial for recurrent high-grade
gliomas showed that the median survival of the patients (n = 53) was 13.6 months with
six patients showing complete response [21]. However, in a subsequent phase III study in
403 patients, clinical endpoints were not met [117].
New results from the earlier phase I clinical trial (NCT01470794) were recently pub-
lished demonstrating that 86% of the patients that lived >2 years had neoantigens deriving
from IDH1, PI3K3CA, EGFR, SYNE1 genes. Interestingly, only 26% of the patients with
<2 years survival had neoantigens arising from these genes, suggesting that neoantigens
arising from driver genes may support Toca+5-FC therapy response. Moreover, the num-
bers of M0 macrophages and NK cells at the tumor site at the time of treatment were
associated with poor response [118]. It is conceivable that these cells contributed to clear-
ance of the virus before its therapeutic effect could take place. Further investigation is
needed to establish if the immune composition could serve as a predictive marker and
whether this is also the case for other oncolytic viruses.
4.4. Oncolytic Measles Virus
Oncolytic measles virus (oMV) has been applied in many Phase I/II clinical trials
against numerous types of cancers including ovarian cancer, pancreatic cancer and glioblas-
toma (GBM) [119]. MV is a single-stranded, negative-sense RNA virus that belongs to the
Paramyxoviridae family [120]. The entry of MV is mediated by the attachment of the viral
Hemagglutinin (H) protein to three known cell surface receptors; the complement regula-
tory protein CD46, the signaling lymphocyte activating molecule (SLAM) or nectin-4 [121].
The wild type strains of MV mainly bind to the SLAM receptor, the attenuated MV Edmon-
ston’s (MV-Edm) vaccine strains enter through CD46 receptor, while nectin-4 can be used
by both wild type and Edm strains [121].
The attenuated MV strains have revealed tropism for infecting and killing glioma
cells, due to the overexpression of the entry receptor CD46 on the cell surface of these
cells [13,122]. Although CD46 is abundantly expressed on glioma cells, facilitating efficient
infection, some glioma cell lines show resistance to oncolysis after the viral entry, indicating
that other processes can affect its oncolytic efficacy [123].
Indeed, a recent study pinpointed the expression of the interferon-induced trans-
membrane protein 1 (IFITM1) gene as the responsible ISG for restricting oMV replication
in transformed human mesenchymal stromal cells [124]. Additionally, in another study
researchers screened eight sarcoma cell lines and found that five of them were susceptible
to the oMV. The resistance in the three remaining sarcoma cell lines was attributed to the
upregulation of the RIG-I and IFITM1 mRNA expression. Interestingly, it was found that
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resistance could be broken by increasing the multiplicity of infection (MOI) in combination
with the pro-drug 5-FC [125].
The fact that oMVs are sensitive to antiviral responses was also highlighted by a
translational study from Kurokawa et al. [123]. Specifically, it was shown that mice bearing
GBM tumors with defective interferon pathway were more responsive to oMV treatment,
producing 387-fold higher infectious progeny virions compared to mice bearing GBM with
intact interferon pathway. Moreover, gene expression analysis of tumor samples from
GBM patients treated with oMV (NCT00390299) showed an inverse correlation of ISGs
expression and viral replication [123].
Taken together, evidence suggests that IFITM1 expression may be a biomarker for
resistance to oMV virotherapy for GBM patients and could help stratify the patients in
oMV trials. Further research needs to be performed in other tumor types to investigate if
this is a pan-cancer biomarker for oMV response.
4.5. Newcastle Disease Virus (NDV)
NDV is an avian paramyxovirus with a negative-sense, single-stranded RNA enclosed
in its viral envelope. It was thought that some NDV strains have oncolytic properties
by taking advantage of the inability of the tumor cells to elicit an anti-viral response due
to deficiencies in IFN pathway [14]. Therefore, the search for markers of resistance to
NDV-mediated oncolysis have focused on the antiviral pathways.
Krishnamurthy et al. showed that NDV susceptibility was linked to impairment of
the type I interferon pathway [126]. Fibrosarcoma cells that were susceptible to NDV
infection were unable to induce IFN-β production [126]. Specifically, the STAT1 and
STAT2 phosphorylation was significantly reduced in the permissive tumor cells, resulting
in reduced expression of ISG mRNAs and IFN-β [126]. In an approach to overcome
resistance, Zamarin et al. engineered an NDV variant expressing an IFNα-antagonist,
which demonstrated enhanced oncolytic activity in melanoma cell lines compared to the
NDV strain without the IFN-antagonist [127].
In contrast with these findings, Mansour et al. revealed that the human non-small-cell
lung cancer cell line A549 was susceptible to NDV oncolysis, despite the production of
high levels of type I IFN response. It was proposed that the restriction mechanism in NDV
oncolysis was based on the expression level of the anti-apoptotic protein Bcl-xl, where
over-expression of Bcl-xl correlates with increased sensitivity to NDV [128]. Moreover, it
was recently demonstrated that STAT3 inhibition suppresses immunogenic cell death (ICD)
by NDV in melanoma tumor cells [129]. Interestingly, Bcl-xl is one of the target genes of
active STAT3 [129].
Another potential marker for NDV cytotoxicity is the status of the autophagy pathway.
Meng et al. showed in U251 glioma cells that NDV exploits the autophagic machinery to in-
crease its replication. In this study, inhibition of BECLIN-1 or ATG5 gene, which are critical
for the autophagosome formation, led to reduced production of NDV [130]. A more recent
study showed autophagy modulators act as sensitizers for NDV in drug-resistant lung can-
cers [131]. On a different note, Puhlmann et al. showed that the oncogenic protein, Rac 1, is
essential for NDV replication and it could confer sensitivity to viral replication [132]. Rac1
is a Rho GTPase protein and is involved in processes like cell proliferation and cytoskeleton
organization [133]. In GBM, it has been shown that Rac1 is important for maintaining the
stemness of GSCs, which may suggest that NDV could potentially be utilized to target the
treatment-resistant cancer stem cell clones within GBM [134].
4.6. Mammalian Orthoreovirus (Reovirus)
Wild type reovirus has been tested clinically for various types of cancer including
GBM, both by local and systemic administration [135,136]. Reovirus is a non-enveloped
virus with 10 segments of dsRNA enclosed in its capsid. The main receptor that wild type
reoviruses use to enter the cells is the junctional adhesion molecule A (JAM-A) [15]. Van
den Hengel et al. tested a panel of primary GBM cell cultures, showing that they exhibit a
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large intertumoral variability in JAM-A expression, suggesting that reovirus efficacy may
be hampered in low JAM-A expressing tumors [56]. Recently a second receptor was shown
to mediate reovirus infection in the central nervous system (CNS), the Nogo receptor
NgR1 [137]. The NgR1 expression in GBM cell lines has been established in various studies,
however in a recent study it was shown that the NgR maturation, and thus expression to
the cell membrane, is inhibited by transforming growth factor-β (TGF-β) 1, which is highly
expressed by GBM cells [138–140]. The cell surface expression of NgR1 in primary GBM
cells is yet to be elucidated.
Reovirus’ natural tropism to replicate and kill tumor cells makes it an ideal candidate
for oncolytic virotherapy. Early on, researchers attempted to elucidate the mechanism
of tumor selectivity. It was found that the constitutively active Ras signaling pathway
potentiates the reovirus replication via inhibition of PKR [141]. Additional studies have
supported that Ras pathway activating mutations enhance reovirus replication [142,143].
Contrary to these findings, Twigger et al. showed that reovirus oncolysis does not depend
on the status of EGFR/Ras/MAPK pathway in squamous cell carcinoma primary cell
lines [144]. Another factor involved in host cell sensitivity to reovirus is determined by
the levels of inhibitors of proteases, such as cathepsin B, that are required to disassemble
the virus in the cytoplasm. Inhibition of these proteases restricts disassembly and inhibits
viral replication [145].
In a clinical phase I trial for high grade gliomas and brain metastasis, the safety
of reovirus after intravenous injection prior to brain surgery was demonstrated. The
reovirus capsid σ3 protein and the virus RNA detection in tumors varied between the
nine trial patients and correlated with the high proliferation index of the tumor cells (Ki67
expression) [136]. The efficacy of reovirus was also evaluated in a clinical trial for non-small
cell lung cancer (NCT01708993), in which reovirus (Reolysin) was injected intravenously. A
post-hoc analysis of the data obtained from this clinical trial showed a favorable trend for
patients with p53 and EGFR mutations [146]. Another clinical trial (NCT01199263) testing
oncolytic reovirus in ovarian cancer patients did not show any clinical benefit and authors
stated that one explanation could be that only 20% of the ovarian cancer patients harbor
Ras mutations [147].
4.7. Oncolytic Poliovirus
Poliovirus is an enterovirus in the Picornaviridae family of single-stranded RNA
vi-ruses. A non-pathogenic oncolytic variant was engineered by replacing the internal
ribo-somal entry site (IRES) of the poliovirus type 1 (Sabin) vaccine strain with the human
rhi-novirus type 2 IRES (PVS-RIPO). The affinity of poliovirus for its cellular receptor
CD155, which is upregulated on GBM cells, provides a unique opportunity target these
tumors [16]. This approach demonstrated potent anti-glioma activity in mouse models
and led to translation to clinical investigation for GBM [17,148]. Impressive results were
obtained in a clinical phase II trial testing the recombinant nonpathogenic polio–rhinovirus
chimera (PVSRIPO), oncolytic virus in 61 patients with recurrent GBM. Twenty-one per-
cent of patients were still alive 36 months after initiation of treatment [149]. The source
of this striking response in a subgroup of patients has yet to be elucidated. However,
intriguingly, transcriptomic analysis revealed a correlation between low tumor mutational
burden, tumor-intrinsic inflammation, and improved survival after PVSRIPO or anti-PD1
immunotherapy in recurrent GBM patients [150]. Further studies are required to confirm
whether these characteristics hold predictive biomarker potential.
4.8. Oncolytic Parvovirus H-1
Oncolytic parvovirus H-1 is a single-stranded DNA rodent protoparvovirus 1 virus [18].
The lack of pre-existing immunity in humans makes parvovirus an interesting oncolytic
virus to explore in the clinic [151]. Oncolytic H-1 parvovirus was administered intratu-
morally and intravenously in recurrent GBM patients in a phase I/IIa trial [152]. Robust
immune response in terms of high infiltration of cytotoxic T cells was observed in the
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oncolytic parvovirus patients in this first study. Furthermore, in peripheral blood of the
patients, specific T cell responses against glioma and viral antigens were detected [152]. Un-
like for many other oncolytic viruses, antiviral type I interferon responses are not evoked by
parvovirus infection [152]. Interestingly, parvovirus infection of GBM cells is followed by
cathepsin B upregulation [152]. Inhibition of cathepsin B protects the glioma cells from par-
vovirus oncolysis, highlighting cathepsin B’s importance in the parvovirus infection [153].
4.9. Oncolytic Vaccinia Virus
Vaccinia virus is a double-stranded DNA virus that belongs to poxvirus family [154].
Its natural tropism to enter the CNS has made it an attractive candidate for systemic
delivery in GBM patients [155]. A phase I/II clinical study for GBM patients is currently
ongoing (NCT03294486), in which patients are treated systemically with the vaccinia virus
TG6002 [156]. Different strains of oncolytic vaccinia virus have been applied for other
types of cancer as well and researchers tried to identify predictive response markers [157].
Zloza et al. identified the inhibitory molecule immunoglobulin-like transcript 2 (ILT2)
on the cell surface of T cells, as a potential biomarker for vaccinia virus immunotherapy
in melanoma patients. Increased expression of ILT2 on T cells was associated with poor
response to oncolytic virotherapy using vaccinia virus [157]. Another study attempted to
identify biomarkers associated with resistance to vaccinia virus therapy in hematological
malignancies [158]. Genes involved in the ubiquitination pathway, DNA damage response
and antigen presentation, among others, were identified and associated with resistance to
vaccinia virus-induced oncolysis [158].
5. Development of Personalized in Vitro Models for OV Selection
It can be concluded that the interplay between the OVs and tumor cells is very complex
and that defining a single biomarker or set of biomarkers predicting efficacy of a specific
OV may not be achievable. An alternative approach is the development of patient-specific
assays to screen a set of OVs and identify the optimal OV for a particular patient. Such
a predictive assay would need to provide information on the efficacy of OV infection,
replication, and oncolysis as well as on the immune response that is mounted by the OVs.
At present, in vitro culture models from patient-derived tumors have become the gold
standard in drug development research for GBM. Our group has developed a preclinical
screening system based on patient-derived low-passage cell cultures under serum-free
conditions for preserving the molecular genetic make-up of the parental tumors [159,160].
Such screening activities have for example led to the identification of viral sensitizers
which enhance the oncolytic activity of delta24-RGD in GBM cells [161]. The screening
system was also applied to assess the efficiency of infection, replication and cell killing by
four different OVs on a panel of primary glioma cell lines, which revealed tremendous
intertumoral heterogeneity in viral sensitivities [56] (and unpublished data). Such panels
of molecularly characterized cell cultures may also help identify new markers of sensitivity
or resistance to tested OVs.
To gain insight in the relationship between oncolytic efficacy and immune stimulation,
a co-culture model of glioma cells and (autologous) immune cell populations, could poten-
tially provide useful insight on the immune response that is triggered after treatment with
different OV candidates, as well as on the relationship between infectivity, oncolysis and
immune activation. For instance, a co-culture of macrophages and delta24-RGD-infected
(and permissive) GSCs revealed a shift of the tumor-supportive macrophages M2 to the
pro-inflammatory M1 [108]. Such approaches are also being taken for other forms of cancer.
A platform has been established for cancers like colorectal and non-small cell lung in which
tumor organoids were co-cultured with autologous T cells derived from the peripheral
blood of the patient [162]. With such model systems, the T cell-mediated cell killing could
be evaluated for individual patients after infection with different OVs [162].
However, the establishment of such primary GSC or organoid-immune cell co-cultures
is time-consuming and may not yield a robust OV therapy recommendation within the
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required timeframe. Furthermore, with serial passaging of primary glioma cells, the diverse
clones that characterize the GBM tumor cannot be maintained [59]. The establishment
of ex vivo 3D tumor model systems directly from fresh tumor tissue may therefore offer
a more attractive approach for performing OV screens on the heterogeneous landscape
of GBM as such models still retain architecture and cellular composition of the original
tumor, including the presence of immune cell infiltrates. We previously reported that
fresh tissue derived organotypic multicellular spheroids (OMS) offer a versatile system
for studying OV infection, replication and tissue penetration [163]. Similarly, fresh GBM
tumor slices have been employed to assess oncolytic myxoma virus efficacy [164]. Other
approaches being developed include the culture of fresh tumor cells in slices, on matrices
and in microfluidic systems [165–167]. Culturing fresh tissue also has limitations, since
the culturing methods generally favor the tumor cells and not the immune cells [168].
Identification of culture conditions supporting all cell populations would also offer an
improvement to these models.
Efforts in the field to generate 3D models from fresh tissue under culture conditions
that support and recapitulate the unique immune tumor microenvironment are expected to
facilitate investigations into both the dynamics of viral infection and replication in tumor
cells as well as the effects thereof on local immune responses [169]. Such systems may in
the future offer a tool to screen multiple OVs for a specific patient and select the optimal
viral treatment within a clinically-relevant timeframe.
6. Conclusions
With the translation of oncolytic virotherapy to clinical trials for GBM patients, im-
pressive responses have been documented in small subgroups of patients. To increase these
response rates, better understanding of factors affecting viral replication, oncolysis and
subsequent immune activation is required for each of the OVs under development. Studies
in clinically-relevant in vitro and in vivo models as well as trial-associated immune and
tumor monitoring studies are crucial for defining these factors and are expected to offer
leads for stratification of patients in future OV trials.
Based on current literature reviews, we have identified factors related to the sensitivity
of GBM tumors for specific OVs including the expression of the viral entry molecules,
activation state of (cell cycle) signaling or autophagy pathways and the induction of specific
antiviral signaling pathways that clear the virus infection (Table 2). These individual
markers of sensitivity or resistance may together yield predictive profiles. However,
further investigations are needed to shed light on the interplay between oncolytic activity
on the tumor cells and the immune system. Ultimately, the complexity of these interactions
in a background of a heterogeneous tumor and interpatient immune status variations,
may require development of personalized ex vivo models to aid in identifying the most
promising OV for a specific patient. The convergence of these developments toward
applicable tools will enable classification of each GBM patient as sensitive or resistant to
specific OVs. Ideally, future clinical trial design will incorporate more than one OV in
parallel arms, such that patients can be stratified to the OV that best matches their tumor
properties and/or immune status (Figure 2). Such a selection and stratification approach is
expected to significantly improve response rates in OV trials for GBM patients.
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Table 2. Potential predictive markers for sensitivity or resistance to OVs.
OV Potential Predictive Marker Effect Tumor Type/ Cell Line
T-VEC STING Resistance Melanoma cell lines [104]
Adenovirus
(Ad5/3-∆24)
MxA Resistance Ovarian carcinoma cell line [110]
High HMGB1 Resistance Patients with advanced metastaticsolid tumors [112]
(∆24-RGD) Cyclin D1 Sensitivity Pancreatic cell line [113]
Vocimagene amiretrorepvec









IFITM1 Resistance Transformed mesenchymalstromal cells [124]
RIG-I Resistance Sarcoma cells [125]
ISG15 Resistance Primary GBM cells [123]
NDV
Bcl-xl Sensitivity A549 cell line [128]
Rac-1 Sensitivity HaCaT A5-RT3 [132]
STAT3 Sensitivity Melanoma cell lines [129]
Reovirus (R124)
JAM-A Sensitivity Primary GBM cells [56]
Cathepsin B Sensitivity Glioma cell line [144]
P53 and EGFR mutations Sensitivity Patients with non-small celllung cancer [145]
Ki-67 Sensitivity Patients with high grade gliomasand metastatic brain tumors [136]
Oncolytic parvovirus H-1 Cathepsin B Sensitivity Glioma cell line [18,151]
Vaccinia virus
Expression of ILT2 on T cells Resistance Melanoma patients [155]
LEF1, STAMBPL1, and SLFN11 Sensitivity myeloid and lymphoid leukemiacell lines [156]
PVRIG, LPP, CECR1, Arhgef6, IRX3,
IGFBP2, and CD1d Resistance
myeloid and lymphoid leukemia
cell lines [156]
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